, /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its research abstracts have been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31–June 4 in Chicago, Illinois.

The selected studies span multiple cancer types—including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and ovarian cancer—highlighting the broad clinical utility of plasma proteomics and the company's continued commitment to advancing personalized treatment strategies through host-response biomarker innovation.

Poster Presentations

Title: Longitudinal Plasma Proteomic Analysis: A Monitoring Strategy for NSCLC Patients Treated with Immunotherapy
Presenter: Yehonatan Elon, PhD, CTO at OncoHost
Session Date: May 31, 2025 | 1:30 PM CDT | Hall A – Posters and Exhibits
Abstract Number: 8579 | Poster Board: 59

This study explores the use of plasma proteomic signatures to dynamically monitor treatment response in NSCLC patients receiving immune checkpoint inhibitors (ICIs). The research identified three distinct proteomic patterns—reflecting drug presence, immune activation, and lung tissue damage—and demonstrated their potential for early identification of non-responders up to 6.6 months before radiologic imaging. A comparative analysis with ctDNA will also be presented.

The abstract is available on the ASCO website here.

Title: A Plasma Proteomics-Based Model for Predicting Response to Neoadjuvant Chemotherapy in Ovarian Cancer
Presenter: Ofer Sharon, MD, CEO at OncoHost
Session Date: June 2, 2025 | 1:30 PM CDT | Hall A – Posters and Exhibits
Abstract Number: 3056 | Poster Board: 371

This research presents a novel computational model based on pre-treatment plasma proteomics that predicts chemotherapy response in high-grade serous ovarian cancer (HGSOC). The study demonstrates the feasibility of using plasma proteomics from pre-treatment blood samples to predict response to neoadjuvant chemotherapy in HGSOC.

The abstract is available on the ASCO website here.

Title: Genomic and Proteomic Predictors of Sites of Metastases in Renal Cell Carcinoma
Presenter: Clara Steiner, MD, Postdoctoral Research Fellow at Dana-Farber Cancer Institute
Session Date: June 2, 2025 | 9:00 AM CDT | Hall A – Posters and Exhibits
Abstract Number: 4538 | Poster Board: 338

Through multi-omics profiling of metastatic RCC patients, this study identifies genomic alternations and circulating proteins associated with specific metastatic sites, including lung, bone, and liver. These findings support the development of non-invasive predictors of metastatic organotropism and may inform future site-specific treatment strategies.

The abstract is available on the ASCO website here.

"Our expanding clinical pipeline and participation in ASCO 2025 represent critical milestones in the evolution of precision oncology," said Ofer Sharon, MD, CEO of OncoHost. "By combining advanced proteomic technologies with AI-driven analytics, we continue to demonstrate the versatility of our platform across tumor types and treatment settings—reinforcing our commitment to amplifying oncologist's insights in making more personalized and effective treatment decisions."

About OncoHost

OncoHost is a technology company headquartered in Binyamina, Israel, and Cary, North Carolina, transforming the approach to precision medicine for improved patient outcomes. OncoHost's proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC™ test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival.

Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

For more information, visit www.oncohost.com, or follow OncoHost on LinkedIn, Twitter, Facebook, and YouTube.

Media Contact:
Mimi Strahl – Ben Simon
Senior Marcom Associate
[email protected]
+972-50-428-1138

SOURCE OncoHost